MALDI

Bruker Announces Share Purchase Agreement to Acquire Molecular Diagnostics Innovator ELITechGroup

Retrieved on: 
Wednesday, February 28, 2024
Medical Devices, Health, Other Science, Research, Science, Biotechnology, Acquisition, Hospital, Infection, Cystic fibrosis, Microbiology, MALDI, Mycobacterium, MDX, Fungal infection, PAI Partners, PAI, COVID, BRKR, Tuberculosis, Hand, Corporation, PCR, HIV, IVD, Partnership

This put option has now been exercised, and the parties have entered into a binding share purchase agreement.

Key Points: 
  • This put option has now been exercised, and the parties have entered into a binding share purchase agreement.
  • ELITechGroup, with over 500 employees and over 40 active patents, develops and commercializes innovative, proprietary molecular diagnostic (MDx) systems and assays, as well as niche biomedical systems and microbiology products.
  • Establishing this unique business within Bruker - a well-respected global life-science tools and specialty diagnostics company - provides an exciting opportunity to further grow our molecular diagnostics, microbiology and biomedical systems portfolios.
  • Upon closing, ELITech is expected to be a stand-alone business within Bruker’s Microbiology and Infection Diagnostics division, as a part of the Bruker CALID Group.

Journal of Pharmaceutical Analysis Articles Provide Novel Insights into Previously Unknown Disease Mechanisms

Retrieved on: 
Tuesday, February 27, 2024
Nerve, Central nervous system, Metabolism, PXR, Alzheimer's disease, Testosterone, PCN, Research, MSI, Diabetic cardiomyopathy, Inflammation, Pathology, Deficit spending, Pregnane X receptor, MALDI, Neurotoxicity, Dysbiosis, JPA, Hippocampus, CYP, Heart failure, DCM, Domestic airport, Phenytoin, Mass spectrometry, PHT, Triglyceride, TMAO, Transplant, Glucocorticoid, Lipid metabolism, Patient, Journal, Glucose, Heart, Mouse, Glycated hemoglobin, Brain

XI'AN, China, Feb. 27, 2024 /PRNewswire/ -- DCM is the leading cause of heart failure in patients with chronic diabetes, with unclear mechanisms and limited treatments. Another mystery is the regulation of cytochrome P450 enzymes (CYPs) in the central nervous system. Moreover, the link between the gut microbiome, microbiota-derived metabolites, and the progression of AD remains unknown. In the December issue of Journal of Pharmaceutical Analysis (JPA), three articles explore the interconnected pathologies of DCM, hippocampal neurotoxicity, and AD, offering a comprehensive insight.

Key Points: 
  • Moreover, the link between the gut microbiome, microbiota-derived metabolites, and the progression of AD remains unknown.
  • In the December issue of Journal of Pharmaceutical Analysis (JPA), three articles explore the interconnected pathologies of DCM, hippocampal neurotoxicity, and AD, offering a comprehensive insight.
  • Their findings, available online on 17 August 2023, were published in Volume 13, Issue 12 of the journal in December 2023.
  • Gut dysbiosis aggravates cognitive deficits, amyloid pathology and lipid metabolism dysregulation in a transgenic mouse model of Alzheimer's disease

Accelerate Diagnostics Announces Collaboration for the Use of the Arc™ System in Combination With Bruker´s MALDI Biotyper®

Retrieved on: 
Monday, November 27, 2023
Economics, Pressure, Microbiology, Clinical trial, Sepsis, FDA, Laboratory, BRKR, MALDI, Blood culture, Acceleration, Sirius (instrumental), Legislation, Fine chemical, Medical device, Bruker

TUCSON, Ariz., Nov. 27, 2023 /PRNewswire/ -- Accelerate Diagnostics, Inc. (NASDAQ: AXDX) an innovator of rapid in vitro diagnostics in microbiology, announced the signing of a collaboration and quality agreement with Bruker Corporation (NASDAQ: BRKR), the provider of the market-leading MALDI Biotyper system for microbial identification. This agreement enables both companies to validate the use of Accelerate Diagnostics' Arc™ system, an innovative, automated positive blood culture sample preparation platform, with Bruker's MALDI Biotyper® sirius instruments and Sepsityper® software for subsequent registration in both the US and EMEA markets.

Key Points: 
  • Designed for clinical laboratories, the Arc™ system has a simple load-and-go workflow that automates direct from positive blood culture sample preparation for downstream microbial identification using Bruker's MALDI Biotyper system.
  • The Arc™ system enables on-demand processing of samples without the need for an overnight culture incubation, reducing the wait time for identification results.
  • "The combination of Bruker's MALDI Biotyper with Accelerate Diagnostics' Arc™ system to automate positive blood culture sample preparation and rapid microbial identification will be a valuable addition to many laboratories.
  • Bruker welcomes this collaboration with Accelerate Diagnostics as both companies are committed to help laboratories in the important fight against sepsis with their leading products" said Wolfgang Pusch, President, Bruker Microbiology & Infection Diagnostics.

BioFlyte Successfully Validates Aerosolized Fentanyl Detection Capabilities

Retrieved on: 
Thursday, September 28, 2023
Research, Software, Other Defense, Medical Devices, Contracts, Infectious Diseases, Hardware, Health Technology, Science, Government Technology, Security, Technology, Biotechnology, Nanotechnology, Health, Public Safety, Defense, White House, Federal Government, State, Local, Homeland Security, Other Health, General Health, Public Policy, Government, Air, Transport, Pharmaceutical, Other Science, Other Technology, Xylazine, MALDI, Face, Classification, History, Ricin, Collection, Small nucleolar RNA R64/Z200 family, V, Paracetamol, Homeland security, Anthrax, Fentanyl, Pittsburgh International Airport, Risk management

“BioFlyte’s mission is to protect people and critical infrastructure, while also ensuring the continuity of operations in the face of evolving biological and chemical threats,” said Todd Sickles, CEO of BioFlyte.

Key Points: 
  • “BioFlyte’s mission is to protect people and critical infrastructure, while also ensuring the continuity of operations in the face of evolving biological and chemical threats,” said Todd Sickles, CEO of BioFlyte.
  • “Key decision makers in government and public safety are struggling to control the flow of fentanyl into the country.
  • Our ability to quickly and accurately detect life-threatening chemical threats like fentanyl, in addition to serious biological agents sets us apart from every other solution on the market.
  • In testing with Avarint, the BioTOF was exposed to both pure fentanyl and fentanyl mixed with common cutting agents such as xylazine and acetaminophen.

Bruker Introduces Novel 4D-Proteomics™ timsTOF® Capabilities

Retrieved on: 
Monday, September 18, 2023
Research, Technology, Medical Supplies, Health Technology, Software, Biotechnology, General Health, Pharmaceutical, Health, Science, Informatics, LC, BRKR, MALDI, Urine, Serum, TIMS, SP3, Pathology, University of Mainz, Proteomics, Demichev, Multimedia, PG, Biomarker, DDA, Assistant, Associate, Harvard Medical School, Plasma, De novo peptide sequencing, Protein, Acquisition, Kyoto University, Saliva, LC-MS, Ultra, CCS, CSF, MS/MS, Hospital, Fluid mechanics, LC/MS, Boston Children's Hospital, Peptide, Fine chemical, Bruker

View the full release here: https://www.businesswire.com/news/home/20230918138030/en/

Key Points: 
  • View the full release here: https://www.businesswire.com/news/home/20230918138030/en/
    Bruker introduces TIMSquant a scalable, CCS-enabled AI-powered label-free quantification algorithm integrated into Bruker ProteoScape™.
  • We leverage the robustness of our timsTOF instruments and real-time Bruker ProteoScape to build large spectral libraries and analyze 1000s of clinical research samples.
  • Bruker is initiating a limited early-access program for midia-PASEF for immunopeptidomics and post-translational modifications (PTMs) on the ultra-sensitive timsTOF Ultra.
  • To all colleagues in search of top-tier high-throughput data, I endorse the PepSep MAX HT.”
    To ensure optimal run conditions for every sample, Bruker introduces TwinScape™, a digital twin for the timsTOF platform, using Bruker ProteoScape software and the Biognosys iRT kit.

BioFlyte Launches First-of-Its-Kind Biothreat Surveillance Pilot Program at Pittsburgh International Airport

Retrieved on: 
Tuesday, August 22, 2023
Hardware, Other Defense, Contracts, Security, Technology, Nanotechnology, Transportation, General Health, Travel, Defense, Air, Transport, Biotechnology, Science, Other Science, Health, PIT, Partnership, Pittsburgh International Airport, Atmosphere, Aviation, Matrix-assisted laser desorption/ionization, Multimedia, HVAC, Collection, Algorithm, Bacteria, Robotics, Virus, Safety, MALDI, Risk management

BioFlyte , a bioaerosol surveillance firm with a disruptive new class of fieldable biological threat collection, detection and identification solutions, today announced a comprehensive pilot program with Pittsburgh International Airport (PIT) to utilize its fieldable mass spectrometer to add a new layer of safety for the airport.

Key Points: 
  • BioFlyte , a bioaerosol surveillance firm with a disruptive new class of fieldable biological threat collection, detection and identification solutions, today announced a comprehensive pilot program with Pittsburgh International Airport (PIT) to utilize its fieldable mass spectrometer to add a new layer of safety for the airport.
  • As a part of this pilot program, one of BioFlyte’s modules is stationed within the airport’s HVAC system to provide continuous, autonomous surveillance of the air moving through the terminals.
  • “This is the first time a biothreat surveillance technology of this caliber has been operationally introduced into this type of complex critical infrastructure,” said Todd Sickles, CEO, BioFlyte.
  • We are a safer, better airport with them onboard.”
    To learn more about this pilot program and to watch the BioFlyte team demo the technology, see the feature and video on PIT’s Blue Sky News .

BioFlyte Raises $5.4M in Series B Financing to Protect Critical Infrastructure from Airborne Biothreats

Retrieved on: 
Thursday, August 10, 2023
Science, Other Science, Biotechnology, Defense, Other Defense, Health, Technology, Other Technology, Airport, Government, Ricin, Collection, Small nucleolar RNA R64/Z200 family, Cottonwood Technology Fund, Bacteria, Anthrax, Safety, Library, Virus, Fentanyl, Pittsburgh International Airport, MALDI, Risk management

BioFlyte will use this new funding to continue scaling its manufacturing and sales operations to meet customer demand and to develop new product configurations that will serve new markets.

Key Points: 
  • BioFlyte will use this new funding to continue scaling its manufacturing and sales operations to meet customer demand and to develop new product configurations that will serve new markets.
  • “This round of funding will allow us to scale our manufacturing operations and create a sales organization to drive market penetration and support our growing customer base,” said Todd Sickles, CEO, BioFlyte.
  • The z200 provides test results in less than five minutes and operates continuously and autonomously in critical infrastructure environments such as airports, arenas, entertainment venues, and commercial and government buildings.
  • The system consists of a wall mount sensor capable of autonomous detection and identification of airborne toxins in real-time.

LSU Mechanical Engineering Professor, AgCenter Receive $10M Grant to Design New Variety of Rice

Retrieved on: 
Tuesday, June 20, 2023
Diet, U.S. Department of Defense Strategy for Operating in Cyberspace, Education, Heat, Atmosphere, NMR, Survival, GHG, Mass spectrometry, Salinity, Natural Resources, LSU, Soil science, Water, Groundwater, LC-MS, Mass spectrometry imaging, Phenotype, Gene, Louisiana State University, Behavior, MALDI, Agriculture

It is the most widely consumed staple food for more than half of the world’s population, which continues to grow each year.

Key Points: 
  • It is the most widely consumed staple food for more than half of the world’s population, which continues to grow each year.
  • With the production of rice increasing, so does the need for water to grow it.
  • In order to not use up nature’s most precious valuable resource—water—one LSU College of Engineering professor is working with the LSU AgCenter to design a new variety of rice that will be able to withstand drought conditions, making rice production fruitful while not exhausting natural resources.
  • Louisiana is the nation’s third-largest rice-producing state behind Arkansas and California, thanks to its warm climate, abundant water, and water-retaining clay soils.

Waters Boosts Resolution and Triples Scan Speed of SELECT SERIES MRT for Metabolomics and MS Imaging

Retrieved on: 
Monday, June 5, 2023
WAT, Mass spectrometry imaging, American Society for Mass Spectrometry, MALDI, University, Waters, ASMS, Urine, Mass spectrometry, DESI, Sheffield Hallam University, Hope, Research, Noetics, Discovery, Scientific Reports, FWHM, SELECT, Metabolomics, Blood, Drug discovery, MRT, UPLC, Waters Corporation, Society, NYSE, Breast cancer, REM, Television, Medical imaging

HOUSTON, June 5, 2023 /PRNewswire/ -- American Society for Mass Spectrometry (ASMS) -- Waters Corporation (NYSE:WAT) today announced new updates to its SELECT SERIES™ MRT System that increases its specificity and utility for UPLC-MS/MS metabolomics and drug discovery applications and for mass spectrometry imaging experiments. The MRT System now offers 50% higher resolution, making it capable of 300,000 FWHM resolution, a 3X faster scan rate, and parts-per-billion mass accuracy.

Key Points: 
  • New resolution enhancement mode (REM) for Waters' multi-reflecting time-of-flight (MRT) mass spectrometer leads to greater specificity and higher sample throughput for metabolomics UPLC™-MS/MS and MS imaging studies.
  • The MRT System now offers 50% higher resolution, making it capable of 300,000 FWHM resolution, a 3X faster scan rate, and parts-per-billion mass accuracy.
  • It is compatible with numerous MS imaging sources including DESI and MALDI, and generates crystal-clear, high-resolution images without compromising mass spectral resolution or accuracy.
  • The new resolution enhancement mode is available as an optional upgrade to currently installed and new SELECT SERIES MRT Systems.

Bruker Introduces New Mycobacteria and Fungi IVD Solutions for MALDI Biotyper®, and a Novel LiquidArray® Gastrointestinal Syndromic Panel

Retrieved on: 
Friday, April 14, 2023
Technology, Medical Devices, Clinical Trials, Health Technology, Software, Other Health, Biotechnology, Hardware, Health, Consumer Electronics, Transfer, Infection, MVZ, MYT, Gastroenteritis, MALDI, BRKR, Workflow, HT, Mycobacterium, PCR, Multimedia, Temperature, Fungus, DK, Congress, Gastrointestinal tract, ECCMID, Nontuberculous mycobacteria, Partner, XT, Laboratory, European, IVD, MBT, Microbiology, Bruker, Vaccine, Medical device

The new MBT Mycobacteria IVD Kit offers a user-friendly, dedicated sample preparation method for mycobacteria cultivated in liquid as well as on solid media.

Key Points: 
  • The new MBT Mycobacteria IVD Kit offers a user-friendly, dedicated sample preparation method for mycobacteria cultivated in liquid as well as on solid media.
  • The MBT Mycobacteria IVD Kit further simplifies the workflow for identification of nontuberculous mycobacteria by MALDI-TOF MS and reduces hands-on time.
  • The new LiquidArray® Gastrointestinal is a syndromic panel that enables the simultaneous detection of up to 26 pathogens causing gastroenteritis.
  • The new LiquidArray® Gastrointestinal is a next-generation syndromic panel with amazing pathogen coverage.